Trends in Formulation eBook
Read the article:
Using a Drug Candidate Screening Strategy to Mitigate Late-Stage Risk
Read the eBook:
Pharmaceutical Technology’s Trends in Formulation eBook
Using a Drug Candidate Screening Strategy to Mitigate Late-Stage Risk
News
Article
Pharmaceutical TechnologyPharmaceutical Technology, Trends in Formulation, October 2022
Volume 2022 eBook
Issue 3
Pages: 4–9
An early drug candidate screening strategy should incorporate clear targets to lessen late-stage failure.
Kalyakan/Stock.adobe.com
Time-to-market remains a significant factor in drug development today, as delays in timelines can often have costly and damaging effects, not only to the drug developer but to the patient. Challenges in the drug development cycle arise early in the drug candidate screening process. In this article, Industry players discuss how technological innovation and advances in analytical approaches enhance early drug candidate screening workflows to help shorten drug discovery and development timelines.
Read this article in Pharmaceutical Technology’s October 2022 Trends in Formulation eBook.
About the author
Feliza Mirasol is science editor for Pharmaceutical Technology.
Article Details
Pharmaceutical Technology
eBook: Trends in Formulation, October 2022
October 2022
Pages: 4–9
Citation
When referring to this article, please cite it as F. Mirasol, “Using a Drug Candidate Screening Strategy to Mitigate Late-Stage Risk," Pharmaceutical Technology Trends in Formulation eBook (October 2022).
Articles in this issue
Small is a Powerful Ingredient for Patient-Centric Formulations
Using a Drug Candidate Screening Strategy to Mitigate Late-Stage Risk
Addressing Developmental Challenges of Gene Therapy Viral Vectors
Improved Formulations to Enable Stable Delivery of Biologics
Nitrosamides–Should They Be Treated the Same as Nitrosamines?
Emerging Applications of Vitamin E TPGS in Drug Delivery
Recent Videos
Related Content
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024Podcast
In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024Podcast
In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
